Top Page
Amplia Therapeutics
(OTC:ATX)
Amplia Therapeutics (ATX) vs. iShares MSCI Australia ETF (EWA)
Amplia Therapeutics Business Overview & Revenue Model
Amplia Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.38M | 3.78M | 4.45M | 1.19M | 1.98M | 1.53M |
| Gross Profit | 2.20M | 3.57M | 4.01M | 1.12M | 1.98M | 1.53M |
| EBITDA | -10.75M | -6.78M | -4.48M | -7.26M | -3.64M | -3.81M |
| Net Income | -7.93M | -6.57M | -4.50M | -6.24M | -3.64M | -2.28M |
Balance Sheet | ||||||
| Total Assets | 44.54M | 22.94M | 14.85M | 18.68M | 24.48M | 10.88M |
| Cash, Cash Equivalents and Short-Term Investments | 29.16M | 10.86M | 3.39M | 9.26M | 14.61M | 1.85M |
| Total Debt | 381.42K | 13.89K | 1.59M | 2.27M | 2.10M | 0.00 |
| Total Liabilities | 1.61M | 1.91M | 3.43M | 2.85M | 2.64M | 539.13K |
| Stockholders Equity | 42.93M | 21.02M | 11.42M | 15.84M | 21.85M | 10.34M |
Cash Flow | ||||||
| Free Cash Flow | -13.39M | -6.89M | -5.13M | -5.31M | -4.42M | -2.92M |
| Operating Cash Flow | -13.36M | -6.89M | -5.13M | -5.29M | -4.40M | -2.92M |
| Investing Cash Flow | -81.65K | -2.07K | -2.23K | -58.42K | -26.64K | -5.35K |
| Financing Cash Flow | 37.99M | 14.32M | -772.98K | -84.22K | 17.19M | 3.66M |
Amplia Therapeutics Technical Analysis
Amplia Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$79.53M | -7.71 | -27.39% | ― | ― | 26.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$20.50M | -9.26 | -1651.76% | ― | -100.00% | 2.86% | |
46 Neutral | AU$25.72M | -5.27 | -157.93% | ― | ― | -36.89% | |
44 Neutral | AU$36.73M | -9.09 | -143.71% | ― | 306.88% | ― | |
40 Underperform | AU$10.57M | -1.79 | -166.70% | ― | ― | ― | |
37 Underperform | AU$13.77M | -1.61 | -628.72% | ― | ― | 31.87% |
Amplia Therapeutics Corporate Events
Amplia Therapeutics has reported updated interim data from its Phase 2a ACCENT trial in metastatic pancreatic cancer, presented at the 2026 ASCO Gastrointestinal Cancer Symposium. The trial, which evaluates narmafotinib in combination with standard chemotherapies gemcitabine and Abraxane, shows a progression-free survival of 7.7 months versus 5.5 months for chemotherapy alone and an overall response rate of 35%, rising to 42% including unconfirmed responses, while maintaining a safety profile comparable to chemotherapy alone. Management says the ASCO GI presentation reinforces Amplia’s positioning among leading oncology developers and highlights the potential of narmafotinib to improve outcomes in advanced pancreatic cancer, complementing its broader clinical strategy that includes the newly opened AMPLICITY trial combining narmafotinib with FOLFIRINOX.
The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has entered a second phase of its preclinical research collaboration with Korean drug screening specialist Next & Bio to further investigate the effects of its FAK inhibitor narmafotinib in combination with experimental kRAS inhibitors on patient-derived pancreatic cancer cells. The extension follows encouraging initial data showing narmafotinib’s activity against kRAS-mutant pancreatic cancer models, and the partners will now explore potential synergistic effects with kRAS inhibitors, a new class of drugs under development for several solid tumours. Amplia sees this next stage as an opportunity to strengthen its scientific case for combination therapies in hard-to-treat pancreatic cancer, enhance the clinical and commercial prospects of narmafotinib and potentially broaden partnering opportunities, while Next & Bio leverages its advanced patient-derived cell platform to support the development of new treatment options in an area of high unmet medical need.
The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics announced a positive development in its ACCENT trial for metastatic pancreatic cancer, where its FAK inhibitor narmafotinib, combined with gemcitabine and nab-paclitaxel, achieved a 35% objective response rate. This result surpasses the 23% response rate of the benchmark MPACT trial, indicating a significant advancement in treatment efficacy. The data will be presented at the Life Sciences Virtual Investor Forum, highlighting Amplia’s potential impact on cancer treatment and its strategic positioning in the pharmaceutical industry.
The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has announced its financial report for the half year ending September 2025, highlighting significant progress in its clinical trials. The company’s lead drug, narmafotinib, has shown promising results in the ACCENT trial for advanced pancreatic cancer, achieving a confirmed response rate of 33%, which is superior to existing treatments. A new trial, AMPLICITY, has also commenced, further exploring narmafotinib’s efficacy in combination with FOLFIRINOX.
The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has received positive feedback from the US FDA regarding its planned Phase 2b/3 trial for narmafotinib, a FAK inhibitor, in combination with gemcitabine and Abraxane for pancreatic cancer. The FDA’s support for the dose comparison design and minimal impact on timelines enhances Amplia’s confidence in proceeding with the trial, which is set to begin in late 2026, potentially strengthening its position in the oncology market.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has announced the issuance of 480,769 unquoted equity securities in the form of Zero Exercise Price Options under an employee incentive scheme. This strategic move is likely aimed at retaining and motivating employees, potentially impacting the company’s operational efficiency and competitive positioning in the biotechnology sector.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has commenced trading on the U.S. OTCQB Venture Market, enhancing its engagement with U.S. investors and expanding its presence in the U.S. market. This move coincides with the company’s AMPLICITY clinical trial for advanced pancreatic cancer opening at five sites in the U.S., and is part of Amplia’s broader strategy to educate investors about its FAK inhibitor program, which includes the promising drug narmafotinib.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has reported significant progress in its clinical trials for narmafotinib, a FAK inhibitor, showing improved outcomes in metastatic pancreatic cancer treatment. The company has achieved key regulatory milestones, including ethics approval for a new trial combining narmafotinib with FOLFIRINOX chemotherapy and securing a patent for its drug formulation, positioning it for further commercial development and potential partnerships.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has received a $3.77 million R&D tax rebate from the Australian Tax Office, which will support the progression of its clinical trials for narmafotinib, a FAK inhibitor. This funding will aid in advancing the ACCENT and AMPLICITY trials, which are exploring narmafotinib’s effectiveness in treating advanced pancreatic cancer, potentially enhancing Amplia’s position in the oncology pharmaceutical industry.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics is expanding its U.S. presence by increasing investor engagement and awareness through a capital markets campaign. This initiative supports its ongoing Phase 2A clinical trial for pancreatic cancer and includes plans to uplist to the OTCQB market, aiming to broaden its U.S. investor base and enhance its market positioning.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.